Literature DB >> 15994870

A combination of genetic polymorphisms increases the risk of progressive disease in chronic hepatitis C.

M M Richardson, E E Powell, H D Barrie, A D Clouston, D M Purdie, J R Jonsson.   

Abstract

BACKGROUND: There is increasing interest in the influence of host genetic factors on hepatic fibrosis, and whether genetic markers can reliably identify subjects at risk of developing severe disease. We hypothesised that hepatitis C virus (HCV) infected subjects with progressive fibrosis, classified using strict criteria based on histology at biopsy in addition to disease duration would be more likely to inherit several genetic polymorphisms associated with disease progression compared with subjects with a low rate of disease progression.
METHODS: We examined polymorphisms in eight genes that have been reported to have an association with hepatic fibrosis.
RESULTS: Associations between polymorphisms in six genes and more rapidly progressing fibrosis were observed, with individual adjusted odds ratios ranging from 2.1 to 4.5. The relationship between rapidly progressing fibrosis and possession of > or =3, > or =4, or > or =5 progression associated alleles was determined and the adjusted odds ratios increased with increasing number of progression associated alleles (9.1, 15.5, and 24.1, respectively). Using logistic regression analysis, a predictive equation was developed and tested using a second cohort of patients with rapidly progressing fibrosis. The predictive equation correctly classified 80% of patients in this second cohort.
CONCLUSIONS: This approach may allow determination of a genetic profile predictive of rapid disease progression in HCV and identify patients warranting more aggressive therapeutic management.

Entities:  

Mesh:

Year:  2005        PMID: 15994870      PMCID: PMC1736103          DOI: 10.1136/jmg.2005.032557

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  11 in total

Review 1.  Genome-wide association studies and genetic risk assessment of liver diseases.

Authors:  Marcin Krawczyk; Roman Müllenbach; Susanne N Weber; Vincent Zimmer; Frank Lammert
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-11-02       Impact factor: 46.802

2.  Combined effect of pro- and anti-inflammatory cytokine gene polymorphisms on susceptibility to liver cirrhosis in Tunisian HCV-infected patients.

Authors:  Nadia Bouzgarrou; Elham Hassen; Olfa Bahri; Sallouha Gabbouj; Nabil Ben Mami; Henda Triki; Lotfi Chouchane
Journal:  Hepatol Int       Date:  2011-02-08       Impact factor: 6.047

3.  Clinical Implications of Krüpple-like Transcription Factor KLF-14 and Certain Micro-RNA (miR-27a, miR-196a2, miR-423) Gene Variations as a Risk Factor in the Genetic Predisposition to PCOS.

Authors:  Rashid Mir; Nizar H Saeedi; Mohammed M Jalal; Malik A Altayar; Jameel Barnawi; Abdullah Hamadi; Faris J Tayeb; Sanad E Alshammari; Nabil Mtiraoui; Mohammed Eltigani M Ali; Faisel M Abuduhier; Mohammad Fahad Ullah
Journal:  J Pers Med       Date:  2022-04-06

4.  Hepatic steatosis in hepatitis C is a storage disease due to HCV interaction with microsomal triglyceride transfer protein (MTP).

Authors:  Silvia Mirandola; David Bowman; Mahmood M Hussain; Alfredo Alberti
Journal:  Nutr Metab (Lond)       Date:  2010-02-23       Impact factor: 4.169

5.  Tumor necrosis factor-alpha 308.2 polymorphism is associated with advanced hepatic fibrosis and higher risk for hepatocellular carcinoma.

Authors:  Jen-Eing Jeng; Jung-Fa Tsai; Lee-Yea Chuang; Mei-Shang Ho; Zu-Yau Lin; Min-Yuh Hsieh; Shin-Chern Chen; Wan-Lung Chuang; Liang-Yen Wang; Ming-Lung Yu; Chia-Yen Dai; Jan-Gowth Chang
Journal:  Neoplasia       Date:  2007-11       Impact factor: 5.715

Review 6.  Molecular and contextual markers of hepatitis C virus and drug abuse.

Authors:  Paul Shapshak; Charurut Somboonwit; Lydia N Drumright; Simon D W Frost; Deborah Commins; Timothy L Tellinghuisen; William K Scott; Robert Duncan; Clyde McCoy; J Bryan Page; Brian Giunta; Francisco Fernandez; Elyse Singer; Andrew Levine; Alireza Minagar; Oluwadayo Oluwadara; Taiwo Kotila; Francesco Chiappelli; John T Sinnott
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

Review 7.  Recognition of genetic factors influencing the progression of hepatitis C : potential for personalized therapy.

Authors:  Julie R Jonsson; David M Purdie; Andrew D Clouston; Elizabeth E Powell
Journal:  Mol Diagn Ther       Date:  2008       Impact factor: 4.074

Review 8.  Clinical Advances in Fibrosis Progression of Chronic Hepatitis B and C.

Authors:  Ye-Jiao Wu; Ming-Yi Xu; Lun-Gen Lu
Journal:  J Clin Transl Hepatol       Date:  2014-12-15

9.  MTP -493G/T gene polymorphism is associated with steatosis in hepatitis C-infected patients.

Authors:  E R F Siqueira; C P M S Oliveira; M L Correa-Giannella; J T Stefano; A M Cavaleiro; M A H Z Fortes; M T C Muniz; F S Silva; L M M B Pereira; F J Carrilho
Journal:  Braz J Med Biol Res       Date:  2011-12-09       Impact factor: 2.590

10.  A polymorphism in the microsomal triglyceride transfer protein can predict the response to antiviral therapy in Egyptian patients with chronic hepatitis C virus genotype 4 infection.

Authors:  Yasmin Saad; Olfat Shaker; Yasser Nassar; Lama Ahmad; Mohamed Said; Gamal Esmat
Journal:  Gut Liver       Date:  2014-10-07       Impact factor: 4.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.